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Abstract. 
 
The spatial organization of transcription-
associated proteins is an important control mechanism 
of eukaryotic gene expression. Here we analyzed the 
nuclear distribution of the transcriptional coactivators 
CREB-binding protein (CBP)/p300 in situ by confocal 
laser scanning microscopy, and in vivo complex forma-
tion by coimmunoprecipitation. A subpopulation of 
CBP and p300 is targeted to active sites of transcription 
and partially colocalizes with hyper- and hypophos-
phorylated RNA polymerase II (pol II) in discrete re-
gions of variable size throughout the nucleus. However, 
the coactivators were found in tight association with hy-
pophosphorylated, but not hyperphosphorylated pol II. 
Transcriptional inhibition induced a relocation of CBP/
p300 and pol II into speckles. Moreover, double and tri-
ple immunoﬂuorescence analyses revealed the pres-
ence of CBP, p300, and pol II in a subset of promyelo-
cytic leukemia (PML) bodies. Our results provide 
evidence for a dynamic spacial link between coactiva-
tors of transcription and the basal transcription machin-
ery in discrete nuclear domains dependent upon the 
transcriptional activity of the cell. The identiﬁcation of 
pol II in CBP/PML-containing nuclear bodies supports 
the idea that transcription takes place at PML bodies.
Key words: transcription • coactivators • nuclear 
body • RNA polymerase II • promyelocytic leukemia
 
Introduction
 
The eukaryotic nucleus is dynamically organized with re-
spect to particular activities such as transcription, RNA
processing, and replication (Singer and Green, 1997; La-
mond and Earnshaw, 1998; Schul et al., 1998a). The cellu-
lar organization of transcription-related factors seems to
be particularly important in facilitating or regulating gene
expression (Stenoien et al., 1998; Kornberg, 1999). In ac-
tively transcribing cells, nascent pre-mRNA transcripts lo-
calize in a nucleoplasm-wide meshwork pattern and in
discrete foci of variable size, as visualized by immunofluo-
rescence after nucleotide incorporation (Jackson et al.,
1993; Wansink et al., 1993). RNA polymerase II (pol II)
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localization coincides with these transcription sites to a
high degree during periods of active transcription (Iborra
et al., 1996; Grande et al., 1997; Zeng et al., 1997; Schul et
al., 1998b). In transcriptionally inactive cells pre-mRNA
transcription is no longer detectable and pol II undergoes
a dynamic relocation into a network of speckles (Zeng et
al., 1997). Mammalian cell nuclei commonly contain 20–40
speckles (Fu and Maniatis, 1990; Spector, 1993). Although
transcription of some genes can occur in or near the pe-
riphery of speckles (Xing et al., 1993; Zhang et al., 1994;
Misteli and Spector, 1998), these structures have been sug-
gested to function primarily as temporary storage sites or
recycling centers for multiple factors required for mRNA
biogenesis (Spector, 1993; Zeng et al., 1997; Lamond and
Earnshaw, 1998; Misteli and Spector, 1998).
Promyelocytic leukemia (PML) protein–containing nu-
clear bodies (PML oncogenic domains; PODs, nuclear do-
main 10; ND10, or Kr bodies) also have been functionally
linked to transcription, e.g., of viral genes (Maul, 1998),
and other nuclear processes such as RNA processing,
transport, and RNP assembly (Doucas and Evans, 1996;
Sternsdorf et al., 1997; Maul 1998; Matera, 1999). PML
bodies appear as 5–30 discrete punctate regions distinct
from speckles after immunofluorescence staining (Brasch
and Ochs, 1992). Direct evidence for a role of PML bodies
in transcription comes from the demonstration of nascent
pol II transcripts within this nuclear body (LaMorte et al.,
1998). In contrast, other groups detected nascent RNA in
the periphery, indicating that the surroundings of the PML
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nuclear bodies are the sites of transcriptional activity
(Grande et al., 1996; Boisvert et al., 2000). Thus, it remains
controversial, whether transcription is occurring in or near
PML bodies.
CREB-binding protein (CBP) and p300 are structurally
and functionally related transcriptional coactivator pro-
teins that operate at the end points of a variety of signal
transduction pathways, thereby modulating specific gene
expression programs involved in cell growth, differentiation,
homeostasis, and viral pathogenesis (for review see Jan-
knecht and Hunter, 1996; Shikama et al., 1997). The ability
of CBP and p300 to interact with multiple, signal-depen-
dent transcription factors suggested that these coactiva-
tors function as signal integrators by coordinating com-
plex signal transduction events at the transcriptional level
(Chrivia et al., 1993; Arany et al., 1994; Arias et al., 1994;
Kwok et al., 1994; Eckner et al., 1994; Lundblad et al.,
1995). CBP and p300 have been proposed to mediate tran-
scription induction via intrinsic and associated histone-
acetylase activities, which may facilitate binding of nuclear
factors to their target sites by destabilizing promoter-bound
nucleosomes (Bannister and Kouzarides, 1996; Ogryzko et
al., 1996; Yang et al., 1996). Additionally, CBP/p300 may
also mediate target gene activation through association
with active pol II complexes, thereby bridging upstream
transcription factors with the general transcription ma-
chinery (Kee et al., 1996; Nakajima et al., 1997a,b; Neish et
al., 1998; Cho et al., 1998).
To investigate step(s) in gene activity modulation in
which CBP/p300 operate, we have compared the spatial
distribution and the characteristics of the association of
the coactivators with RNA polymerase II and active tran-
scription in mammalian nuclei.
 
Materials and Methods
 
Cell Culture
 
HEp-2, HeLa, MCF-7, and T-24 cells were obtained from the American
Tissue Culture Collection and grown as recommended. Transcriptional in-
hibition was induced by adding 
 
a
 
-Amanitin (
 
a
 
-am; 10 
 
m
 
g/ml working con-
centration; Sigma-Aldrich) for 8 h.
 
Antibodies
 
Polyclonal rabbit antibodies CBP-C20, CBP-A22 (both from Santa Cruz
Biotechnology, Inc.), CBP-5614, CBP-5729, and CBP-254-256 have been
described previously (Arias et al., 1994; Kee et al., 1996; Bex et al., 1998;
Doucas et al., 1999). Antibody 254-256 is directed against aa 634–648 of
CBP (Arias et al., 1994), and was affinity purified from a peptide column
for immunohistochemistry and immunoblots. mAb p300-CT (clone
RW128; Upstate Biotechnology) has been described previously (Bex et
al., 1998). Polyclonal rabbit antibodies p300-N15 and p300-C20 were pur-
chased from Santa Cruz Biotechnology, Inc. To detect pol II, monoclonal
antibodies mara3 (Patturajan et al., 1998; kindly donated by Bart Sefton,
Salk Institute, La Jolla, CA), and 8WG16 (Thompson et al., 1989; kindly
provided by Nancy Thompson, University of Madison, WI), were used.
PML bodies were visualized in immunofluorescence studies with rat anti-
bodies directed against the PML protein or the SP100 protein (kindly pro-
vided by Thomas Sternsdorf, Heinrich-Pette-Institute, Hamburg, Ger-
many). The nuclear mitotic apparatus protein NuMa, coiled bodies,
nucleoli, and centromeres were stained with human autoimmune sera ob-
tained from the reference serum bank of the W.M. Keck Autoimmune
Disease Center, The Scripps Research Institute.
 
Immunocytochemistry
 
Cells grown on coverslips were fixed by treatment with methanol at
 
2
 
20
 
8
 
C for 5 min followed by acetone (prechilled to 
 
2
 
20
 
8
 
C) for 2 min, or
by incubation in 2% paraformaldehyde for 20 min at room temperature
followed by acetone treatment (prechilled to 
 
2
 
20
 
8
 
C) for 2 min. Immuno-
fluorescence was performed as previously described (von Mikecz et al.,
1997). For dual or triple immunofluorescence staining, primary antibodies
from different sources (mouse, rabbit, human, or rat) were used simulta-
neously and detected with species-specific secondary antibodies linked to
fluorescein, rhodamine, or Cy5 (Jackson ImmunoResearch Laboratories).
 
Confocal Microscopy and Scatter Diagrams
 
Samples were scanned with a Zeiss LSM 510 laser scanning confocal de-
vice attached to an Axioplan 2 microscope using a 63
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 Plan-Apochromat
oil objective (Carl Zeiss, Inc.), or on a Fluoview laser scanning system
from Olympus. Fluorescein, rhodamine, or Cy5 dyes were excited by laser
light at a 488-, 543-, or 633-nm wavelength, respectively. To avoid bleed-
through effects in double or triple staining experiments, each dye was
scanned independently using the multitracking function of the LSM 510
unit. Single optical sections were selected either by eye-scanning the sam-
ple in z axis for optimal fluorescence signals, or taken from stack projec-
tions. Images were electronically merged using the LSM 510 (Carl Zeiss,
Inc.) software and stored as TIFF files. Figures were assembled from the
TIFF files using Adobe Photoshop software. Colocalization scatter dia-
grams were generated with the LSM 510 software. A scatter diagram rep-
resents a comparison of pixel coincidence between two images (i.e., red
and green). All pixels having the same position in both images are consid-
ered a pair. Of every pair of pixels (P1, P2) from the two source images,
the brightness level of pixel P1 is interpreted as the x coordinate, and that
of pixel P2 as the y coordinate of the scatter diagram. The value of the
pixel thus addressed is increased by one every time, up to the maximum
number of pixels used. This way, each pixel of the scatter diagram is a
value that shows how often a particular pair of pixels has occurred. Two
completely overlapping images would result in a straight, diagonal line
from bottom left to top right of the scatter diagram. Accordingly, two pro-
teins displaying a high degree of colocalization would produce diagonal
club-like patterns from bottom right to top left.
 
In Situ Immunolabeling of Nascent RNA Transcripts
 
Bromouridine triphosphate (BrU) was used for detecting ongoing RNA
synthesis in permeabilized HEp-2 cells by immunodetection with antibody
against bromodeoxyuridine (Boehringer) as previously described (Zhang
et al., 1999), according to protocols developed by Jackson et al. (1993) and
Wansink et al. (1993).
 
Immunoprecipitation and Immunoblotting
 
Immunoprecipitations were performed with HEp-2 whole cell lysates ac-
cording to protocols described by Kee et al. (1996). A rabbit anti–mouse
bridging antibody (Jackson ImmunoResearch Laboratories) was added in
precipitations using mAbs. Immunoprecipitates were resuspended in SDS
loading buffer and analyzed by SDS-PAGE. For immunoblotting, gels
were transferred onto nitrocellulose and specific proteins were visualized
using enhanced chemiluminescence according to the manufacturer’s in-
structions (Amersham Pharmacia Biotech).
 
Results
 
CBP and p300 Localize to Distinct Nuclear Domains
 
To study the spatial relationship between CBP/p300 and
pol II, several antibodies directed against different pep-
tides from CBP, p300, and pol II were analyzed by immu-
nofluorescence experiments on HEp-2 cells followed by
confocal laser scanning microscopy and by immunoblot-
ting (Fig. 1). The epitopes recognized by antibodies used
in this study are schematically depicted in Fig. 1 (left).
Three antibodies (A22, C20, and 254-256) identified CBP
in a meshwork staining pattern throughout the nucleo-
plasm overlaid with several brighter foci of variable size
(Fig. 1, micrographs, top), and with dot-like structures
(Fig. 1, A22, inset). In addition, affinity-purified antibody 
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254-256 detected CBP in a speckle-like pattern when
used at higher working concentration (Fig. 1, top, 254-
256, inset). The latter observation can be explained by
the dependence of immunofluorescence staining on the
working concentration of the primary antibody, as has
previously been described in detail for other anti-speckle
antibodies (Neugebauer and Roth, 1997). However, A22
and C20 did not decorate speckles when used at higher
working concentration (data not shown). Antibodies N15
and CT revealed nuclear staining patterns of p300 that
were very similar to those obtained for CBP (Fig. 1, mi-
crographs, middle). Similar localization patterns of CBP
and p300 staining were observed in different mammalian
cell lines, including HeLa, MCF-7, and T24, and using dif-
ferent cell fixation protocols (von Mikecz, A., and P.
Hemmerich, unpublished results). The specificity of anti-
CBP and anti-p300 antibodies was confirmed by immuno-
blotting on nuclear extracts from HEp-2 cells (Fig. 1,
immunoblot, right). All antibodies recognized a single
protein band at 
 
z
 
250 kD corresponding to the molecular
weight of CBP and p300 (Chrivia et al., 1993; Eckner et
al., 1994).
Nuclear distribution of pol II was detected with mAb
mara3, which specifically targets phosphorylated epitopes
in the COOH-terminal domain of pol II (pol IIo, Pattura-
jan et al., 1998), and 8WG16, which detects hypophosphor-
ylated forms of pol II (pol IIa, Thompson et al., 1989;
Bregman et al., 1995). Both pol II isoforms are believed to
have distinct functional roles in transcriptional initiation
(pol IIa) and elongation (pol IIo; Dahmus, 1995). The
transition of pol II from initiation to elongation is associ-
ated with phosphorylation of the COOH-terminal domain
of subunit IIa (Payne et al., 1989). Mara3 and 8WG16 pro-
duced a broad staining of the nonnucleolar portion of the
nucleus of HEp-2 cells overlaid with discrete sites of pre-
ferred staining (Fig. 1, micrographs, bottom). In addition,
at higher antibody concentrations, mara3 stained speckle-
like structures (Fig. 1, micrograph, bottom, mara3, inset).
We did not observe speckle-like staining of HEp-2 cells
using 8WG16 (data not shown). In addition to the broad
nucleoplasmic staining, 8WG16 revealed 
 
z
 
3–10 bright
dot-like foci in 
 
.
 
50% of HEp-2 cells (Fig. 1, micrograph,
bottom row, 8WG16 and inset). Immunoblot analyses con-
firmed the specificity of the anti–pol II antibodies. Mara3
preferentially reacted with the hyperphosphorylated form
of pol II (IIo), whereas 8WG16 predominantly recognized
hypophosphorylated forms of pol II (IIa) (Fig. 1, immuno-
blot, bottom).
Figure 1. Specificity of anti-CBP/p300 and anti–pol II antibodies. (Left) Schematic representation of CBP, p300, and pol II primary
structure (CTD, COOH-terminal domain; P denotes the phosphorylated CTD). The epitopes recognized by antibodies used in this
study are indicated. (Center) For the micrographs, HEp-2 cells grown on coverslips were fixed and labeled with anti-CBP–specific anti-
bodies A-22, C-20, and 254-256, p300-specific antibodies N15 and CT, or anti–pol II antibodies mara3 and 8WG16. Immunofluores-
cence staining was analyzed by confocal laser scanning microscopy. Single confocal sections are shown for each antibody as indicated.
Areas marked by a rectangle are shown enlarged as insets in the respective images. Antibodies 254-256 against CBP and mara3 against
phosphorylated pol II revealed speckle-like staining in a subpopulation of HEp-2 cell nuclei when used at higher antibody concentra-
tions (insets; numbers indicate dilution factor). (Right) In immunoblots prepared from HEp-2 cell nuclear extracts, anti-CBP and anti-
p300 antibodies recognized a single band migrating at z250 kD. Mara3 predominantly recognizes hyperphosphorylated forms of pol II
(IIo), whereas antibody 8WG16 predominantly recognizes hypophosphorylated pol II (IIa) in immunoblots of nuclear extracts. 
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CBP/p300 Are Targeted to Active Sites of Transcription
 
Since CBP/p300 are believed to function as bridging mole-
cules between transcription factors and the basal tran-
scription machinery, we investigated the spatial relation-
ship of the coactivators with the largest subunit of pol II
and active sites of transcription. The staining patterns of
pol IIo and pol IIa were compared with nucleoplasmic
CBP distribution in double-labeling experiments, followed
by confocal microscopy (Fig. 2, a and b). The overlay im-
ages show that the nucleoplasmic meshwork staining pat-
terns of CBP partially overlapped with pol IIo and pol IIa
(Fig. 2, a and b). CBP and pol II did not occupy the same
discrete domains, rather they appeared to be present in in-
dividual irregularly shaped nucleoplasmic structures that
partially overlapped (Fig. 2; see magnified areas in insets).
The merged images also revealed multiple regions and
dot-like structures of CBP and pol II that did not colocal-
ize, indicating the existence of nuclear domains of exclu-
sive localization of either CBP or pol II. We also analyzed
the nuclear distribution of CBP with respect to transcrip-
tion sites by in situ transcriptional run-on experiments
(Fig. 2 c). Nascent transcripts in HEp-2 nuclei were la-
beled with BrU and detected with anti-bromodeoxyuridine
antibodies. Double labeling revealed partial overlap be-
tween CBP staining and sites of transcription (Fig. 2 c).
However, many domains exclusively contain CBP and no
or little nascent RNA, and vice versa. Similar results were
obtained when p300 labeling was compared with pol II
staining or BrU incorporation (data not shown). No colo-
calization could be detected between CBP or p300 and
NuMa, a 200-kD transcription-unrelated nuclear protein
(Cleveland, 1995) that served as a control (Fig. 2 d and
data not shown, respectively), indicating that the regions
of overlap between CBP/p300 and pol II, or transcription,
are not fortuitous.
Colocalization scatter diagrams were generated to as-
sess the degree of colocalization between CBP and pol II,
BrU incorporation, or NuMa. A scatter diagram repre-
Figure 2. CBP/p300 is tar-
geted to active sites of tran-
scription. Fixed HEp-2 cells
were double labeled with
anti-CBP antibodies C20
(a–d, red) and mara3 against
pol IIo (a, green), 8WG16
against pol IIa (b, green),
anti-BrU antibody detecting
nascent RNA after in situ
incorporation of BrU (c,
green), or antinuclear mi-
totic apparatus protein
(NuMa) antibody (d, green).
Single optical sections of
each fluorochrome were re-
corded in independent scans.
Rectangle-marked areas of
each image are shown en-
larged as green signal only
(upper insets), red signal only
(middle insets), or as the
overlay image (bottom in-
sets). The nucleolar BrU
staining in c is presumably
due to rRNA transcription by
RNA polymerase I. (e, f),
Colocalization scatter dia-
grams were generated from
the cells shown in c and d, re-
spectively. (g) Western blot
analysis of pol IIo, pol IIa,
CBP, p300, and NuMa recov-
ered from immunoprecipi-
tates of HEp-2 cell protein ly-
sates using mara3 (a-Pol IIo),
8WG16 (a-Pol IIa), anti-CBP
(a-CBP), anti-p300 (a-p300),
or anti-NuMa (a-Numa) anti-
body. In each case 20% of in-
put extract (INPUT) is
shown. 
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sents a comparison of pixel coincidence between two im-
ages (see Materials and Methods). The scatter diagram of
BrU/CBP staining shows a club-shaped distribution from
bottom left to upper right, indicative of a considerable spa-
tial coincidence between CBP and BrU staining (Fig. 2 e).
In contrast, the scatter diagram application of NuMa/CBP
was very diffuse, indicating little overlap between NuMa
and CBP distribution (Fig. 2 f). Scatter diagrams gener-
ated from pol IIo/CBP and pol IIa/CBP comparisons also
showed club-like distributions (data not shown).
To test whether the colocalization between CBP/p300
and pol II correlates with in vivo complex formation of
these proteins we performed coimmunoprecipitation stud-
ies on protein lysates from HEp-2 cell nuclei. This analysis
revealed that pol IIo is not present in immunoprecipitates
from CBP or p300 antibodies (Fig. 2 g, row 1, lanes 3 and
4). In contrast, 
 
z
 
10–20% of pol IIa was recovered from
CBP or p300 immunoprecipitates (Fig. 2 g, row 2, compare
lane 2 with lanes 3 and 4, respectively). A similar fraction
of endogenous CBP or p300 was recovered from pol IIa
immunoprecipitates (Fig. 2 g, rows 3 and 4). As a control,
anti-NuMa immunoprecipitation complexes did not con-
tain pol II, CBP, or p300 protein (Fig. 2 g, rows 1–4, lane
5). NuMa was not detected in immunoprecipitates of pol
IIa, CBP, or p300 (Fig. 2 g, row 5, lanes 2–4). Taken to-
gether, these results suggest that a subpopulation of CBP
and p300 is in close vicinity to sites of mRNA transcription
and in tight association with hypo-, but not hyperphosphor-
ylated pol II. Thus, although CBP/p300 colocalized with
pol IIo and pol IIa in situ, the coactivators appear to par-
ticipate only in pol II a–containing complexes in vivo.
 
Dynamic Relocation of CBP/p300 into Speckles
 
In transcriptionally inhibited cells, factors involved in
mRNA biogenesis including pol II redistribute to a classi-
cal speckle distribution pattern (Spector, 1993; Bregman
et al., 1995). A speckled pattern of pol II localization has
been shown to be characteristic of poorly transcribing or
transcriptionally inactive cells because they fail to show in-
corporation of BrU into nascent mRNA in nuclear run-on
experiments (Zeng et al., 1997). 
 
a
 
-am, a compound that
completely blocks pol II–mediated transcription (Lindell
et al., 1970), was used to experimentally induce the redis-
tribution of pol II into speckle domains (Fig. 3). In HEp-2
cells treated with 
 
a
 
-am (10 
 
m
 
g/ml), CBP (detected by anti-
body 254-256) redistributed into speckle structures where
it strongly colocalized with pol IIo and splicing factor
SC35 (Fig. 3, top and middle). A subpopulation of p300
exhibited a similar redistribution into pol II–containing
speckles in transcriptionally inhibited cells (Fig. 3, bot-
tom). However, it should be noted that CBP and p300
were not detected in all pol II–containing speckles and
vice versa, thus indicating a heterogeneity of the molecular
composition of speckles with respect to the coactivators.
Pol II could not be detected in speckle structures of tran-
scriptionally inhibited cells using antibody 8WG16 (Fig.
4 h). This result indicates that speckle-bound pol II is hy-
Figure 3. Transcriptional inhibition causes a redistribution of CBP and p300 in HEp-2 cells. HEp-2 cells were a-am–treated (10 mg/ml)
to arrest transcription and processed for double labeling using the following antibody combinations: top row, 254-256 against CBP
(green) and mara3 against pol II (red); middle row: 254-256 against CBP (green) and anti-SC35 antibody (red); bottom row: N-15
against p300 (green) and mara3 against pol II (red). Single confocal sections are shown. Areas marked by a rectangle are shown en-
larged on the right side of each overlay image. Note that CBP was stained with antibody 254-256 which preferentially recognizes CBP in
speckles (see Fig. 1). 
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perphosphorylated, which is in agreement with prior ob-
servations (Bregman et al., 1995). Taken together, these
results suggest that a fraction of CBP and p300 is dynami-
cally redistributed together with pol IIo into speckled do-
mains in transcriptionally inactive cells.
 
PML Bodies Contain CBP, p300, and pol II
 
CBP has been shown recently to be recruited by PML pro-
tein to nuclear bodies in which both proteins may directly
participate in modulation of nuclear receptor–induced
transcriptional activation (Doucas et al., 1999). In addi-
tion, nascent RNA has been detected within LaMorte et
al. (1998), or in the periphery of PML bodies (Grande et
al., 1996; Boisvert et al., 2000). These results and our ob-
servation that a subfraction of CBP and p300 colocalizes
with pol II in discrete nuclear domains prompted us to test
whether p300 and pol II are also present in PML bodies.
Colocalization of CBP with the PML bodies was analyzed
in double-labeling experiments using antibody A22 to de-
tect dot-localized CBP. The merged image and the color-
separated enlargements shown in Fig. 4 a confirmed the
presence of CBP in PML bodies of HEp-2 cell nuclei, but
also identified PML bodies that contained little or no CBP
(Fig. 4 a, insets). Using antibody against an NH
 
2
 
-terminal
peptide of p300 we were also able to identify the p300 co-
activator in PML protein–containing nuclear bodies (Fig. 4
b). Similar to CBP, p300 was present in only a subset of
PML bodies (Fig. 4 b, merged image and insets). These re-
sults indicate that the molecular composition of PML bod-
ies can vary with respect to the transcriptional coactivators
CBP/p300. We did not observe colocalization of CBP or
p300 with coiled bodies, the nucleolus, or centromeres
(data not shown), indicating that nuclear substructure lo-
calization of the coactivators is restricted to PML protein–
containing domains.
The spatial relationship of PML bodies and pol II was
also analyzed in double-labeling experiments. Cells exhib-
iting the broad nucleoplasmic meshwork staining of pol
IIo overlaid with sites of preferred localization produced
by mara3 did not reveal any colocalizing structures (Fig. 4
c). In contrast, some of the dot structures labeled by anti-
body 8WG16 colocalized with PML protein–containing
nuclear bodies (Fig. 4 d). However, some PML bodies do
not contain pol IIa and some of the pol IIa–containing dot
structures do not contain PML protein (Fig. 4 d, insets).
Pol-IIa–containing nuclear dots, as detected with mAB
8WG16, also colocalized with some of the p300 dot-shaped
foci (data not shown). The finding that only a subset of
PML bodies colocalized with CBP/p300 or pol IIa raised
the question whether the same nuclear bodies contain
both the coactivators and the enzyme. We addressed this
question by performing triple-labeling immunofluores-
cence experiments. This analysis demonstrated that CBP,
pol IIa, and the PML protein can be detected in the same
nuclear bodies (Fig. 4 e). Taken together these results
show that the CBP/p300 coactivators are associated with
pol IIa and PML protein in a subset of nuclear bodies and
suggest that they may function as modulators of active
transcription in or near these structures.
When transcription was arrested by 
 
a
 
-am (10 
 
m
 
g/ml),
PML protein dissociated into numerous smaller domains
scattered throughout the nucleoplasm (Fig. 4, f–h). Dual
labeling of such cells revealed that CBP, as detected with
antibody A22, colocalized with these domains (Fig. 4 f ). In
drug-treated cells, speckle-associated RNA polymerase, as
stained with mara3, did not colocalize with the scattered
PML domains, although a few speckles can be seen to
Figure 4. PML bodies contain CBP, p300 and pol II. HEp-2 cells were double labeled with a rat antibody against the PML protein (a–d
and f–h, green; e, blue), and antibodies CBP-A22 (a, e, and f, red), p300-N15 (b, red), mara3 against pol IIo (c and g, red), and 8WG16
against pol IIa (d and h, red). In e, triple fluorescence is shown with the following antibody combination: 8WG16 against pol IIa (as de-
tected with fluorescein-labeled anti–mouse antibody, green), A22 against CBP (as detected with rhodamine-labeled anti–rabbit anti-
body, red), and anti-PML antibody (as detected with Cy5-labeled anti–rat antibody, blue pseudo-colored). In f–h, cells were treated
with a-AM (10 mg/ml). Areas marked by a rectangle are shown enlarged on the right side of each overlay image as insets. Each inset
represents one dye only, except for the bottom insets, which represent the merged image. Note that CBP was stained with antibody
A22, which preferentially recognizes CBP in PML bodies (see Fig. 1). 
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overlap with PML protein-containing domains (Fig. 4 g).
In contrast, a large number of PML foci appeared to con-
tain pol IIa, as revealed with antibody 8WG16 (Fig. 4 h).
These observations confirm the association of CBP, pol
IIa, and PML protein in discrete nuclear domains and sug-
gest that a subfraction of CBP and pol IIa is dynamically
reorganized into many small PML protein–containing nu-
clear foci in transcriptionally inactive cells.
 
Discussion
 
The transcriptional coactivators CBP/p300 are believed to
connect DNA-bound transcription factors to the transcrip-
tion machinery (Kwok et al., 1994; Kee et al., 1996; Naka-
jima et al., 1997a,b; Neish et al., 1998; Cho et al., 1998). In
addition, CBP/p300 have been proposed to induce tran-
scription activation via intrinsic (Bannister and Kouza-
rides, 1996; Ogryzko et al., 1996) and associated (Yang et
al., 1996) histone acetylase activities that may facilitate
binding of nuclear factors to their target sites by destabi-
lizing promoter-bound nucleosomes (Montminy, 1997).
Thus, the coactivators may function as a transcriptional
scaffold that enables the holoenzyme and regulatory mole-
cules to be recruited to and assembled at relevant sites of
transcriptional activity (Shikama et al., 1997; Parvin and
Young, 1998; Torchia et al., 1998).
Here, we show by confocal microscopy that the nuclear
distribution of CBP/p300 partially coincides with that of
hyper- and hypophosphorylated pol II and active sites of
transcription. The pattern and degree of colocalization be-
tween CBP/p300 and pol II throughout the nucleoplasm
was very similar to the colocalization characteristics of
CBP/p300 and sites of transcription. Colocalization studies
of transcription factors with sites of BrU incorporation or
pol II domains frequently reveal a partial overlap (van
Steensel et al., 1995; Grande et al., 1997; Schul et al.,
1998b; Stenoien et al., 1998). Obviously, CBP/p300 coacti-
vators share this property with some of these transcription
factors (Grande et al., 1997), and also other chromatin re-
modeling coactivator complexes, such as human SWI/SNF
(Reyes et al., 1997). There is a high degree of colocaliza-
tion between hyper- and hypophosphorylated pol II with
sites of nascent RNA, indicating that both forms of RNA
polymerases are in close vicinity to ongoing transcription
(Grande et al., 1997; Zeng et al., 1997; Schul et al., 1998b).
These observations and the finding that CBP/p300 (and
other transcription-related factors) are associated with
only a limited number of BrU foci (and/or pol II domains)
suggest that the coactivators are dynamically recruited to a
subfraction of nuclear sites with transcriptional activity at
a given time. In such subfractions of nuclear sites, CBP/
p300 might also associate with specific transcription-related
factors. For example, BRCA1, a tumor suppressor protein
with properties of a transcription factor, associates func-
tionally and colocalizes partially with p300 in interphase
nuclei of HeLa cells (Pao et al., 2000). Moreover, a sub-
fraction of BRCA1 has been found to copurify with pol II
in immunoprecipitation analyses (Scully et al., 1997). CBP/
p300 domains that are not spatially related to active tran-
scription may serve as storage, or supply sites, or be in-
volved in other transcription-related events such as initia-
tion complex regeneration.
It is believed that pol IIa participates in initiation-compe-
tent forms of pol II complexes and pol IIo in elongation-
competent forms (Payne et al., 1989; Dahmus, 1995). Al-
though both pol IIo and pol IIa colocalized with CBP/p300
in the nucleoplasm, only pol IIa was found in complex with
the coactivators in vivo (Fig. 2). This observation confirms
the finding that p300 specifically interacts with the non-
phosphorylated form of purified pol II complexes (Cho et
al., 1998), and that CBP copurifies with pol II complexes
precipitated with anti–pol IIa antibody (Kee et al., 1996).
Taken together, CBP may serve as a bridging/coactivating/
chromatin-remodeling factor during transcriptional initia-
tion, but may be separated from phosphorylated pol II
during elongation. In vivo, the interaction between CBP/
p300 and pol IIa seems to be mediated either by RNA he-
licase A (Nakajima et al., 1997a,b), or by direct binding
of the COOH-terminal half of CBP/p300 (Cho et al.,
1998). The recent identification of “zinc bundles” as puta-
tive protein–protein interaction modules in the COOH-
terminal CH3 domain of CBP/p300 (Newton et al., 2000)
suggests that this domain may contribute to the interaction
between the coactivators and pol IIa.
When transcription was arrested by specific inhibitors,
CBP/p300 redistributed to pol IIo–containing minimal
domains corresponding to speckles (Fig. 4). Speckles are
characterized by an accumulation of factors involved in
mRNA biogenesis, mainly splicing factors (Spector, 1993).
Our results and other studies indeed revealed colocaliza-
tion of CBP with splicing factor Sm and SC-35 in speckle
structures, but not in the more diffusely stained compart-
ment of the nucleoplasm (Bex et al., 1998; Fig. 3, and data
not shown, respectively). However, we were not able to
detect Sm protein or other splicing factors in immunopre-
cipitates of CBP, suggesting that there is no functional re-
lationship between splicing and CBP (von Mikecz, A., and
M. Montminy, unpublished results). It has been proposed
that speckles may function as storage places supplying ac-
tive gene loci with factors needed for mRNA biogenesis
(Antoniou et al., 1993; Gui et al., 1994; Misteli et al., 1997;
Zeng et al., 1997; Lamond and Earnshaw, 1998; Misteli
and Spector, 1998). If speckles serve as depots for CBP/
p300 in transcriptionally inactive cells, it is conceivable
that the “stored” coactivators are dynamically recruited
together with pol II from speckles to active loci of tran-
scription (or other sites) throughout the nucleoplasm in
transcriptionally active cells.
We also demonstrated that CBP/p300 colocalize with
pol IIa in a subset of PML bodies. Although a variety of
nuclear processes have been suggested to take place at or
near PML bodies, the function of these structures is un-
known (Doucas and Evans, 1996; Sternsdorf et al., 1997;
Maul, 1998; Matera, 1999). They do not seem to be major
sites of splicing factor localization (Grande et al., 1996); in-
stead, proteins associated with these nuclear domains
show properties of transcriptional modulators (Doucas
and Evans, 1996; Bloch et al., 1999; Doucas et al., 1999).
Most importantly, LaMorte et al. have identified nascent
RNA within nuclear bodies, including PML bodies, by in
vivo nucleic acid labeling (1998). However, it was shown
by analytical transmission microscopy that PML nuclear
bodies do not accumulate RNA (Boisvert et al., 2000), but
that newly synthesized RNA is associated with the periph- 
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ery of the PML bodies (Grande et al., 1996; Boisvert et al.,
2000). The contradictory results might be due to (a) usage
of different techniques and (b) different cell lines, since
PML body number, structure, composition, and thus func-
tion can vary considerably depending on the cell type
(Maul, 1998). The presence of PML protein, CBP, and pol
IIa in the same PML bodies (Fig. 4) suggests that they may
serve as supply or recycling sites of preformed initiation
complexes for transcription of gene loci that are localized
adjacent to PML bodies. Such complexes may be recruited
from the core to PML body–associated genes to facilitate
and regulate the expression of these genes. A similar
model has recently been proposed for coiled bodies (Schul
et al., 1998b).
Several viral transforming factors, including the ade-
noviral E1A protein, the SV40 T antigen, and Tax from
HTLV-1 interact with CBP/p300 to modulate transcrip-
tional activity of target genes (for review see Shikama
et al., 1997). Some of these proteins target PML bod-
ies, causing a dramatic redistribution of PML body pro-
teins, including PML itself, to transcription sites scattered
throughout the nucleoplasm (Doucas et al., 1996; Maul,
1998). Viral proteins may disrupt transcription of PML
body–specific genes and/or target transcription (initiation)
complexes containing PML, CBP/p300, and pol II within
the PML bodies in order to recruit such complexes to
genes whose expression is important for efficient virus
propagation. We are confident that identification of the
genes expressed at PML bodies will provide further insight
into PML nuclear body function and molecular mecha-
nisms of virus propagation and evasion of the host im-
mune defense as well.
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